PainReform Ltd.
PainReform Ltd. (PRFX) Financial Performance & Income Statement Overview
Review PainReform Ltd. (PRFX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
PainReform Ltd. (PRFX) Income Statement & Financial Overview
Analyze PainReform Ltd.’s PRFX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $4000.00 | $4000.00 |
| Gross Profit | $0.00 | $0.00 | -$4000.00 | -$4000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | -$392.14B |
| R&D Expenses | $149000.00 | $149000.00 | $6.67M | $4.74M |
| SG&A Expenses | $732500.00 | $732500.00 | $680000.00 | $819000.00 |
| Operating Expenses | $881500.00 | $881500.00 | $7.34M | $5.56M |
| Total Costs & Expenses | $881500.00 | $881500.00 | $7.34M | $5.57M |
| Interest Income | $0.00 | $0.00 | $34000.00 | $64000.00 |
| Interest Expense | $0.00 | $0.00 | $4000.00 | $5000.00 |
| Depreciation & Amortization | $4000.00 | $4000.00 | $4000.00 | $4000.00 |
| EBITDA | -$877500.00 | -$877500.00 | -$7.34M | -$5.56M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | -$545172.68B |
| Operating Income | -$881500.00 | -$881500.00 | -$7.34M | -$5.57M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | -$545564.82B |
| Other Income/Expenses (Net) | $500.00 | $500.00 | $33000.00 | $59000.00 |
| Income Before Tax | -$881000.00 | -$881000.00 | -$7.31M | -$5.51M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | -$539780.75B |
| Income Tax Expense | $4000.00 | $4000.00 | $0.00 | $0.00 |
| Net Income | -$885000.00 | -$885000.00 | -$7.31M | -$5.51M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | -$539780.75B |
| EPS | -$0.60 | -$0.60 | -$50.60 | -$65.22 |
| Diluted EPS | -$0.60 | -$0.60 | -$50.60 | -$65.22 |
| Weighted Avg Shares Outstanding | $1.47M | $1.47M | $144510.00 | $84426.00 |
| Weighted Avg Shares Outstanding (Diluted) | $1.47M | $1.47M | $144510.00 | $84426.00 |
Financial performance has remained strong, with revenue growing from $0.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$881500.00 in Q4 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$877500.00. Net income rose to -$885000.00, keeping EPS at -$0.60. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan